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More than 30 years of double-blind placebo controlled antidepressant efficacy studies have consis tently shown that 30 to 40% of moderately to severely depressed patients improve with placebo treatment (Klerman and Cole 1965; Stark and Hardison 1985; Brown et a1. 1988) . Recent data suggest that these placebo response rates, which have been widely repli cated over the past 30 years, may actually be underes timates. Some studies of the newer antidepressants show placebo response rates close to 50% (Brown et al. the psychotherapies (expectation of improvement, support, mobilization of hope) are provided with pill placebo treatment.
The placebo response in depression has been viewed as a nuisance rather than as a therapeutic and research opportunity. I propose that the initial treatment for selected depressed patients should be four to six weeks of placebo. Patients so treated should be informed that the placebo pill contains no drug but that this treatment can be helpful. [Neuropsychopharmacology 10:265-269, 1994J 1992; C. Beasley, personal communication 1991). [One explanation for this apparent increase in the placebo response is that the relative paucity of side effects with the newer drugs makes the results of placebo-controlled studies less biased by knowledge of which patients are and are not on "active" drug.]
Although among moderately to severely depressed patients the response rate to antidepressants (60 to 70%)
is consistently better than that to placebo, the differ ence in response rates to these two treatment modali ties is only about 35%. an expert; an explanation for the condition; and a heal ing ritual promoting positive expectation and reversal of demoralization (Frank and Frank 1991) .
Expectation is probably the best studied component of the placebo response. In a variety of naturalistic studies expectation of improvement has been shown to be positively correlated with treatment outcome (Frank and Frank 1991) . And when expectation is manipulated in experimental paradigms the effect of a pharmacologically inert substance is directly related to the expected effect; when subjects given a pharmaco logically inert substance are told that they have received caffeine, alcohol, or an analgesic they report subjective experiences and show behavioral and some of the phys iologic changes typical of these substances (Kirsch 1985) .
Pill ingestion itself may well contribute to the ther apeutic effect of placebo treatment (Frank and Frank 1991) . There are no studies examining the effect of pill ingestion per se on depression. But there are data sug gesting that pill ingestion in itself can influence health.
In a study assessing propranolol's effect on mortality in myocardial infarction survivors, more than 2,000 men and women who had survived a myocardial infarction were randomized to receive either propranolol or placebo (Horwitz et al. 1990 ). At one-year follow up, patients who had taken propranolol regularly (more than 75% of prescribed medication) had half the mor tality rate of those who had taken it less regularly. No surprise. But the same relationship held for placebo; patients who took placebo regularly also had half the mortality rate of those who took it less regularly. The relationship between adherence to placebo treatment and mortality could not be accounted for by differences between good and poor adherers on psychosocial and medical factors that influence mortality (Horwitz et al. 1990 ).
The apparent health-promoting effects of pill inges tion have been attributed to the fact that in our culture medication symbolizes the physician's healing power.
Adding to the psychological benefIts of a pill's symbolic value may be conditioning effects derived from previ ous positive experiences with medicine (Voudouris et al. 1985) .
Studies of placebo response in depression provide some guidelines as to which patients treated with placebo are most likely to improve. The most consis-tent and robust predictor of placebo response is epi sode duration . For patients depressed less than three months placebo response rates hover around 50% whereas for those depressed more than a year the placebo response falls to less than 30% (Khan and Brown 1991 The comprehensive evaluation, in addition to providing the clinician with information necessary for diagnosis, appears to have some therapeutic benefIt in itself. Some patients seeking psychotherapy seem to improve as a result of the initial assessment alone (Frank and Frank 1991) . As a critical component of the healing ritual the evaluation is likely to foster the placebo re sponse.
The placebo treatment should involve the provision of pharmacologicall y inert capsules taken daily in a rou tine fashion and weekly or biweekly assessments by an interested kind person who will assess the patient's progress, provide an opportunity for the patient to ver balize distress, and provide practical advice as needed.
These visits should be 15 to 30 minutes long.
In presenting this treatment recommendation to the patient, I envision a dialogue along the following lines:
"Mrs. Jones, the type of depression you have has been treated in the past with either antidepressant medicine or psychotherapy, one of the talking therapies. These two treatments are still widely used and are options for you. There is a third kind of treatment, less expensive for you and less likely to cause side effects, which also helps many people with your condition. This treatment involves taking one of these pills twice a day and com ing to our office every two weeks to let us know how outpatients. Only one was reluctant to take the placebo pills. These data, along with the willingness of many depressed patients to participate in placebo-controlled antidepressant efficacy studies knowing that they have a good chance of receiving placebo, suggest that placebo treatment is not necessarily objectionable. The extent to which depressed patients would accept, reject, or prefer placebo treatment is at this point largely a mat ter of speculation. The Park and Covi study does not provide a defInitive answer to this question, but it does warn us that assumptions about patient acceptance of placebo, no matter how reasonable, may be incorrect.
Placebo treatment will not be effective if both patient and clinician know that the placebo pill is pharmacologically in ert. four spontaneously reported that the pills were the most effective medicine ever prescribed for them, and (4) fIve patients expressed a desire to continue taking the pills beyond the study period (Park and Covi 1965) .
This single small study does not tell us much about how depressed patients will respond to undisguised placebo, but it does provide defInitive information on one point: assumptions about patient response to placebo, no matter how apparently self evident, need to be tested.
Improvement with placebo is transient; it is not as real or durable as the improvement that occurs with antidepres sant treatment. Two studies offer data bearing on this issue. Quitkin and his associates (1993) examined re lapse rates in depressed patients with mixed diagnosis and severity who had responded to six weeks of treat ment with imipramine, phenelzine, or placebo. Dur ing weeks seven to twelve of double-blind continua tion treatment relapse occurred in 9% of the patients on phenelzine, 12% of those on imipramine, and 31 % of those on placebo, a signifIcant difference in relapse rates. Shea and her associates (1992) did an eighteen month follow up study of patients with major depres sion who had responded to sixteen weeks of treatment with cognitive behavior therapy, interpersonal therapy, imipramine, or placebo. For all patients entering treat ment and having follow up data, the percent who re covered and remained well during the follow up period did not differ signifIcantly among the four treatments.
For patients who recovered after 16 weeks of treatment rates of relapse during the follow up period did not differ signifIcantly among the four treatments, 36% for those treated with cognitive behavior therapy, 33% for those treated with interpersonal therapy, 50% for those treated with imipramine, and 33% for those treated with placebo.
It would appear from the available data that the majority of patients who recover with placebo stay well beyond the acute treatment phase. Whether or not im provement with placebo endures as long as that with antidepressants is as yet unclear.
Since the psychotherapies and pill placebo do not appear to differ in effectiveness, why not provide psychotherapy? The bulk of evidence pertaining to the active ingredients of the psychotherapies for depression supports the com mon factor hypothesis (Frank and Frank 1991; Robin son et al. 1990) , and the common factors are provided in placebo treatment. J am proposing pill placebo in stead of psychotherapy because pill placebo is the less expensive alternative; it requires less training, fewer NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.4 qualifIcations, and can probably be delivered in less time.
The term "placebo" comes with unfortunate bag gage. Latin for "I shall please," it is the fIrst word of the vespers for the dead. In the twelfth century these vespers were commonly referred to as placebos (Sha piro 1964). By the fourteenth century placebo had be come a secular and pejorative term; it meant servile flat terer, sycophant, toady (Shapiro 1964) . This usage probably derived from depreciation of profes3ional mourners, those paid to sing placebos (Shapiro 1964 ).
The pejorative connotation stuck when placebo en tered the medical lexicon. It was fIrst defIned as "a com monplace method or medicine" (Motherby 1785), com monplace meaning common, trite, and pedestrian (Shapiro 1964) . A bit later placebo received a defInition that has endured: "any medicine adapted more to please than benefIt the patient" (Fox 1803). In the twen tieth century pharmacologic inactivity was added to the defInition.
Thus "placebo" brings with it connotations of de ception and inauthenticity. The effectiveness of placebo in depression is troublesome in itself; it impugns the validity of our most treasured treatments, it impedes the development of new treatments, it threatens our livelihood. Rather than continuing to view the placebo response as an embarrassing nuisance, I suggest that we harness it. If only 20% of the patients now treated with antidepressants could be as effectively treated with placebo (and the data suggest that this is a conserva tive estimate) the saving in health care costs would be about 40 million dollars (Rice et al. 1985) . There are other gains to be had as well. Adding placebo to the treat ment arsenal would inevitably lead to sharper distinc tions between patients who do and do not require an tidepressants, to identifIcation of treatment relevant subtypes, and to greater precision in treatment se lection.
